Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Leonard Altman

Allergy & Immunology Seattle, WA Medical Doctor

NPI 1407892466 CMS profile 291017

9725 3Rd Ave Ne Ste 500, Seattle, WA 98115

Open in the dashboard

General payments

$80,755

269 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leonard Altman of Seattle, WA is reported in the CMS Open Payments database as having received $80,755 across 269 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $697 7
2024 General $5,748 37
2023 General $1,936 35
2022 General $23,155 44
2021 General $9,354 53
2020 General $10,428 19
2019 General $29,437 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leonard Altman
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Leonard Altman were reported at $697. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Leonard Altman Allergy & Immunology median Middle half National median
2019 $29,437 $594 $163–$1,512 $163
2020 $10,428 $426 $106–$1,233 $114
2021 $9,354 $638 $157–$1,708 $132
2022 $23,155 $790 $205–$1,961 $149
2023 $1,936 $852 $220–$2,147 $160
2024 $5,748 $865 $203–$2,267 $164
2025 $697 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. BioCryst US Sales Co., LLC $22,719 46 payments
  2. Shire North American Group Inc $18,471 31 payments
  3. Pharming Healthcare, Inc. $12,382 22 payments
  4. Cardinal Health 110, LLC $9,450 13 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $7,536 18 payments
  6. AstraZeneca Pharmaceuticals LP $3,136 52 payments
  7. BioCryst Pharmaceuticals, Inc. $2,750 1 payment
  8. Genzyme Corporation $2,029 27 payments
  9. Novartis Pharmaceuticals Corporation $285 14 payments
  10. ALK-Abello, Inc $263 5 payments
  11. Other $1,736 40 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $36,430 16 payments
  2. Consulting Fee $22,510 21 payments
  3. Food and Beverage $10,555 208 payments
  4. Honoraria $7,750 3 payments
  5. Travel and Lodging $3,511 21 payments
Products named General payments · program years 2019–2025
  1. Orladeyo $22,719 46 payments
  2. CINRYZE $18,677 25 payments
  3. RUCONEST $9,669 19 payments
  4. TAKHZYRO Immunology $5,101 3 payments
  5. JOENJA $2,587 2 payments
  6. DUPIXENT $1,649 19 payments
  7. FASENRA Respiratory $1,454 23 payments
  8. TAKHZYRO Genetic Disease $768 15 payments
  9. FASENRA Respiratory $562 14 payments
  10. TEZSPIRE $424 6 payments
  11. Other $3,177 93 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$1,140

Medicare's payments for the services billed

Medicare patients

12

Average age 67

Services billed

144

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Heart failure 0%
Ischemic heart disease 0%
Atrial fibrillation 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JOENJA
  • Pharming Healthcare, Inc. $2,587
$2,587 — —
DUPIXENT
  • GENZYME CORPORATION $488
$488 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $285
$285 — —
Orladeyo
  • BioCryst US Sales Co., LLC $266
$266 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $154
$154 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

269 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record